A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.

APHP, Paris

APHP, Paris

APHP (Paris Grenelle), Paris

CHU Amiens, Amiens

CHU Angers, Angers

Institut Sainte Catherine, Avignon

CHU Besançon, Besançon

CHU Bordeaux, Bordeaux

CHRU Brest, Brest

Centre Chirurgie Urinaire et d'Andrologie, Cabestany

CHU Clermont-Ferrand, Clermont-Ferrand

APHP (Créteil), Créteil

Centre Hospitalier Annecy-Genevois, Épagny

CHU Grenoble, Grenoble

CHU Lille, Lille

CHU Limoges, Limoges

Centre Léon Bérard, Lyon

Hôpital Edouard Herriot, Lyon

Polyclinique de Gentilly, Nancy

CHU Nice, Nice

Institut Mutualiste Montsouris, Paris

Hospices civils de Lyon, Pierre-Bénite

CH Quimper, Quimper

CHU Reims, Reims

Hôpital Foch, Suresnes

Oncopole CHU Toulouse, Toulouse

CHRU Tours, Tours

Institut Gustave Roussy, Villejuif